MYDA Advisors’s Voyager Therapeutics VYGR Stock Holding History

MYDA Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,000	Closed	-$71K	–	206
2022 Q2	$71K	Buy	+12,000	New	+$81.1K	0.02%	170

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MYDA Advisors's VYGR Position: Q3 2022 in Review

MYDA Advisors sold out of Voyager Therapeutics (VYGR) in Q3 2022, closing a stake of 12,000 shares — an estimated $71K sold.

MYDA Advisors first reported a position in VYGR in Q2 2022 and held it in 1 quarter. The position peaked at $71K in Q2 2022. 69 funds tracked by Wall St. Rank hold VYGR as of Q3 2022.

MYDA Advisors reported no remaining Voyager Therapeutics position as of Q3 2022 after selling out during the quarter.
MYDA Advisors sold 12,000 Voyager Therapeutics shares in Q3 2022, an estimated $71K.
MYDA Advisors first reported a position in Voyager Therapeutics in Q2 2022 and held it in 1 quarter.
MYDA Advisors's Voyager Therapeutics position peaked at $71K in Q2 2022.
69 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2022.

Based on MYDA Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.